GlassScriptPhysician profile
Evans Kyei-Nimako
NPI 1871506287
$1,294.54
in general payments reported to CMS, 2019-2025
15 companies · $68.23 in 2025
The $68.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $83.82 · 2021: $316 · 2022: $160 · 2023: $109 · 2024: $217 · 2025: $68.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.77 | 2019-2024 | Farxiga |
| Pfizer INC. | $161.07 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $122.76 | 2020-2022 | |
| Gilead Sciences, INC. | $112.63 | 2021-2025 | Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.06 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.43 | 2019-2024 | Xarelto |
| Vifor Pharma, INC. | $68.88 | 2019-2020 | |
| Melinta Therapeutics, LLC | $65.36 | 2019-2022 | |
| Chiesi USA, INC. | $31.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.22 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.86 | 2023 | Lifevest |
| Abbvie INC. | $18.19 | 2021 | |
| Astellas Pharma US INC | $16.19 | 2019 | |
| Allergan, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evans Kyei-Nimako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.